| Basics |
Rigel Pharmaceuticals, Inc.
Rigel Pharmaceuticals Inc is a clinical-stage biotechnology company. It discovers and develops novel, small-molecule drugs for the treatment of inflammatory/autoimmune diseases, as well as for certain cancers and metabolic diseases.
|
| IPO Date: |
December 7, 2000 |
| Sector: |
Healthcare |
| Industry: |
Biotech |
| Market Cap: |
$350.66M |
| Activated in VL: |
True |
| Average Daily Range |
| Avg Daily Range: |
$0.21 | 2.82%
|
| Avg Daily Range (30 D): |
$0.54 | 2.76%
|
| Avg Daily Range (90 D): |
$0.60 | 3.00%
|
| Institutional Daily Volume |
| Avg Daily Volume: |
1M |
| Avg Daily Volume (30 D): |
.17M |
| Avg Daily Volume (90 D): |
.17M |
| Trade Size |
| Avg Trade Size (Sh.): |
236 |
| Avg Trade Size (Sh.) (30 D): |
50 |
| Avg Trade Size (Sh.) (90 D): |
51 |
| Institutional Trades |
| Total Inst.Trades: |
1,618 |
| Avg Inst. Trade: |
$1.36M |
| Avg Inst. Trade (30 D): |
$1.07M |
| Avg Inst. Trade (90 D): |
$2.47M |
| Avg Inst. Trade Volume: |
.04M |
| Avg Inst. Trades (Per Day): |
1 |
| Market Closing Trades |
| Avg Closing Trade: |
$1.51M |
| Avg Closing Trade (30 D): |
$.68M |
| Avg Closing Trade (90 D): |
$1.54M |
| Avg Closing Volume: |
56.1K |
|
|
|
|
| Financials |
| |
TTM |
Q1 2025 |
Q4 2024 |
|
Basic EPS
|
$2.1
|
$.64
|
$.81
|
|
Diluted EPS
|
$2.08
|
$.63
|
$.81
|
|
Revenue
|
$ 203.08M
|
$ 53.33M
|
$ 57.6M
|
|
Gross Profit
|
$ 182.05M
|
$ 48.92M
|
$ 51.81M
|
|
Net Income / Loss
|
$ 37.18M
|
$ 11.45M
|
$ 14.34M
|
|
Operating Income / Loss
|
$ 43.93M
|
$ 12.77M
|
$ 16.66M
|
|
Cost of Revenue
|
$ 21.03M
|
$ 4.41M
|
$ 5.79M
|
|
Net Cash Flow
|
$ 20.21M
|
$ -10.96M
|
$ 5.05M
|
|
PE Ratio
|
9.56
|
|
|
| Splits |
|
Jun 27, 2024:
1:10
|
|
Jun 25, 2003:
1:9
|
|
